[1]
|
中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版) [J]. 中国循环杂志, 2016, 31(10): 937-950.
|
[2]
|
Mach, F., Baigent, C., Catapano, A.-L., et al. (2019) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Atherosclerosis, 290, 140-205.
|
[3]
|
中华医学会心血管病学分会动脉粥样硬化与冠心病学组, 中华心血管病杂志编辑委员会. 超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J]. 中华心血管病杂志, 2020, 48(4): 280-281.
|
[4]
|
Samuel, E., Watford, M., Egolum, U.-O., et al. (2022) Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280221105169
|
[5]
|
Bays, H., Cohen, D.-E., Chalasani, N., et al. (2014) An Assessment by the Statin Liver Safety Task Force: 2014 Update. Journal of Clini-cal Lipidology, 8, S47-S57. https://doi.org/10.1016/j.jacl.2014.02.011
|
[6]
|
Stroes, E.-S., Thompson, P.D., Corsini, A., et al. (2015) Statin-Associated Muscle Symptoms: Impact on Statin Therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 36, 1012-1022. https://doi.org/10.1093/eurheartj/ehv043
|
[7]
|
Lin, X.-L., Xiao, L.-L., Tang, Z.-H., et al. (2018) Role of PCSK9 in Lipid Metabolism and Atherosclerosis. Biomedicine & Pharmacotherapy, 104, 36-44. https://doi.org/10.1016/j.biopha.2018.05.024
|
[8]
|
Tavori, H., Fan, D., Blakemore, J.-L., et al. (2013) Serum Pro-protein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Recip-rocal Regulation. Circulation, 127, 2403-2413.
https://doi.org/10.1161/CIRCULATIONAHA.113.001592
|
[9]
|
Frank-Kamenetsky, M., Grefhorst, A. anderson, N.-N., et al. (2008) Therapeutic RNAi Targeting PCSK9 Acutely Lowers Plasma Cholesterol in Rodents and LDL Cho-lesterol in Nonhuman Primates. Proceedings of the National Academy of Sciences of the United States of America, 105, 11915-11920. https://doi.org/10.1073/pnas.0805434105
|
[10]
|
Barale, C., Melchionda, E., Morotti, A., et al. (2021) PCSK9 Biology and Its Role in Atherothrombosis. International Journal of Molecular Sciences, 22, 5880. https://doi.org/10.3390/ijms22115880
|
[11]
|
Gallego-Colon, E., Daum, A. and Yosefy, C. (2020) Statins and PCSK9 Inhibitors: A New Lipid-Lowering Therapy. European Journal of Pharmacology, 878, Article ID: 173114. https://doi.org/10.1016/j.ejphar.2020.173114
|
[12]
|
Stein, E.-A., Mellis, S., Yancopoulos, G.-D., et al. (2012) Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. The New England Journal of Medicine, 366, 1108-1118. https://doi.org/10.1056/NEJMoa1105803
|
[13]
|
Stoekenbroek, R.-M., Kallend, D., Wijngaard, P.-L., et al. (2018) Inclisiran for the Treatment of Cardiovascular Disease: The ORION Clinical Development Program. Future Cardiology, 14, 433-442.
https://doi.org/10.2217/fca-2018-0067
|
[14]
|
Zhang, X.-L., Zhu, Q.-Q., Zhu, L., et al. (2015) Safety and Efficacy of anti-PCSK9 Antibodies: A Meta-Analysis of 25 Randomized, Controlled Trials. BMC Medicine, 13, Article No. 123. https://doi.org/10.1186/s12916-015-0358-8
|
[15]
|
Sabatine, M.-S. (2019) PCSK9 Inhibitors: Clinical Evidence and Implementation. Nature Reviews Cardiology, 16, 155-165. https://doi.org/10.1038/s41569-018-0107-8
|
[16]
|
Rallidis, L.-S. (2020) The Changing Landscape of Lipid-Lowering Therapy after the New ESC/EAS Guidelines for the Management of Dyslipidaemias: Launching the Era of Triple Hypo-lipidaemic Therapy in Very High Risk Patients. Atherosclerosis, 292, 231-233. https://doi.org/10.1016/j.atherosclerosis.2019.11.009
|
[17]
|
Burnett, H., Fahrbach, K., Cichewicz, A., et al. (2022) Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients with Hypercholesterolemia at Increased Car-diovascular Risk: A Network Meta-Analysis. Current Medical Research and Opinion, 38, 777-784. https://doi.org/10.1080/03007995.2022.2049164
|
[18]
|
German, C.-A. and Shapiro, M.-D. (2020) Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. BioDrugs, 34, 1-9. https://doi.org/10.1007/s40259-019-00399-6
|
[19]
|
孟凡华, 付真彦. 一种新型的治疗血脂异常的干扰小RNA药物Inclisiran [J]. 心血管病学进展, 2021, 42(2): 167-170.
|
[20]
|
周杰, 陈各才. PCSK9抑制剂与心血管事件关系的研究进展[J]. 海南医学, 2022, 33(6): 778-782.
|
[21]
|
Lamb, Y.-N. (2021) Inclisiran: First Approval. Drugs, 81, 389-395. https://doi.org/10.1007/s40265-021-01473-6
|
[22]
|
Tomlinson, B., Chow, E., Chan, P., et al. (2021) An Evaluation of the Pharmacokinetics of Inclisiran in the Treatment of Atherosclerotic Cardiovascular Disease. Expert Opinion on Drug Metabolism & Toxicology, 17, 1353-1361.
https://doi.org/10.1080/17425255.2021.2029402
|
[23]
|
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., et al. (2014) Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and the Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-Blind, Place-bo-Controlled, Phase 1 Trial. The Lancet, 383, 60-68.
https://doi.org/10.1016/S0140-6736(13)61914-5
|
[24]
|
Fitzgerald, K., White, S., Borodovsky, A., et al. (2017) A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. The New England Journal of Medicine, 376, 41-51. https://doi.org/10.1056/NEJMoa1609243
|
[25]
|
Ray, K.-K., Stoekenbroek, R.-M., Kallend, D., et al. (2018) Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Circulation, 138, 1304-1316.
https://doi.org/10.1161/CIRCULATIONAHA.118.034710
|
[26]
|
Ray, K.-K., Landmesser, U., Leiter, L.-A., et al. (2017) Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. The New England Journal of Medicine, 376, 1430-1440.
https://doi.org/10.1056/NEJMoa1615758
|
[27]
|
Banerjee, Y., Pantea, S.-A., Cicero, A.F.G., et al. (2022) Inclisiran: A Small Interfering RNA Strategy Targeting PCSK9 to Treat Hypercholesterolemia. Expert Opinion on Drug Safety, 21, 9-20.
https://doi.org/10.1080/14740338.2022.1988568
|
[28]
|
Ray, K.-K., Wright, R.-S., Kallend, D., et al. (2020) Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. The New England Journal of Medicine, 382, 1507-1519. https://doi.org/10.1056/NEJMoa1912387
|
[29]
|
Reijman, M.-D., Schweizer, A., Peterson, A.L.H., et al. (2022) Rationale and Design of Two Trials Assessing the Efficacy, Safety, and Tolerability of Inclisiran in Adolescents with Homozygous and Heterozygous Familial Hypercholesterolaemia. European Journal of Preventive Cardiology, 29, 1361-1368. https://doi.org/10.1093/eurjpc/zwac025
|
[30]
|
Robinson, J.-G., Farnier, M., Krempf, M., et al. (2015) Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. The New England Journal of Medicine, 372, 1489-1499.
https://doi.org/10.1056/NEJMoa1501031
|
[31]
|
Sabatine, M.-S., Giugliano, R.-P., Wiviott, S.-D., et al. (2015) Effi-cacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. The New England Journal of Medicine, 372, 1500-1509.
https://doi.org/10.1056/NEJMoa1500858
|
[32]
|
Landmesser, U., Haghikia, A., Leiter, L.-A., et al. (2021) Effect of Inclisiran, the Small-Interfering RNA against Proprotein Convertase Subtilisin/Kexin Type 9, on Platelets, Immune Cells, and Immunological Biomarkers: A Pre-Specified Analysis from ORION-1. Cardiovascular Research, 117, 284-291. https://doi.org/10.1093/cvr/cvaa077
|
[33]
|
Kallend, D., Stoekenbroek, R., He, Y., et al. (2022) Pharmacokinetics and Pharmacodynamics of Inclisiran, a Small Interfering RNA Therapy, in Patients with Hepatic Impairment. Journal of Clinical Lipidology, 16, 208-219.
https://doi.org/10.1016/j.jacl.2022.01.001
|
[34]
|
Zijlstra, L.-E., Trompet, S., Mooijaart, S.-P., et al. (2020) Renal Im-pairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran. Mayo Clinic Proceedings, 95, 12-14.
https://doi.org/10.1016/j.mayocp.2019.11.010
|
[35]
|
Asbeutah, A.A.A., Asbeutah, S.-A. and Abu-Assi, M.-A. (2020) A Meta-Analysis of Cardiovascular Outcomes in Patients with Hypercholesterolemia Treated with Inclisiran. American Journal of Cardiology, 128, 218-219.
https://doi.org/10.1016/j.amjcard.2020.05.024
|